PS01New Insights and Challenges in Managing Chronic GVHDStephanie LeeFred Hutch Cancer Center, USACV
Plenary Session 1: State of the Art in Cell Therapy
PL01-1Mesenchymal Stem Cell TherapyKatarina Le BlancKarolinska Institutet, SwedenCV
PL01-2Natural Killer Cell-Based Cancer TherapyDan KaufmanUniversity of California San Diego, USACV
Plenary Session 2: Alternative Donors
PL02-1How to Improve the Outcome of CBTVanderson RochaUniversity of São Paulo, BrazilCV
PL02-1Trends and Future of the HSCT Using Mismatched DonorsAnna SuredaCatalan Institute of Oncology, SpainCV
Plenary Session 3: HSCT in Myeloid Diseases
PL03-1Biology and Strategy to Prevent and Treat Post-HSCT Relapse in Myeloid DiseasesJohn F. DiPersioWashington University in St. Louis, USACV
Scientific Session 1: Dealing with Practical Issues of Transplantation in Aplastic Anemia
SS01-1Optimal Strategy of Transplantation in Fanconi AnemiaJae Wook LeeThe Catholic University of Korea, KoreaCV
SS01-2Choice of Appropriate Conditioning Regimens for Aplastic AnemiaNelli BejanyanMoffitt Cancer Center, USACV
SS01-3Mutational Landscape of Severe Aplastic Anemia and Implications for TherapyWilliam HoganMayo Clinic, USACV
Scientific Session 2: Immunotherapy for Lymphoid Malignancy in the Post-CAR T Era
SS02-1Novel Strategies to Overcome Relapsed/Refractory Multiple MyelomaSuzanne TrudelUniversity of Toronto, CanadaCV
SS02-2Novel Immunotherapy for Relapsed and Refractory B-Cell LymphomasWon Seog KimSungkyunkwan University School of Medicine, KoreaCV
SS02-3Best Positioning of Immunotherapy in Adult B-Cell ALLMark R. LitzowMayo Clinic, USACV
Scientific Session 3: Transplantation Related Immunology
SS03-1Immune Reconstitution after HSCTStefan NierkensPrincess Máxima Center for Pediatric Oncology, NetherlandsCV
SS03-2Proteomics in HSCTSophie PaczesnyMedical University of South Carolina, USACV
SS03-3GVHD ImmunologyGeoffrey R. HillFred Hutchinson Cancer Center, USACV
Scientific Session 4: Divergent Approaches to the Use of Autologous Hematopoietic Stem Cell Transplantation
SS04-1NK Cells in Autologous Stem Cell TransplantationHareth NahiKarolinska Institutet, Sweden
SS04-2Homology Directed Repair based Gene Editing (HDR-Editing): A Precise and Versatile Method to Engineer Hematopoietic Stem Cells to Treat Rare and Common DiseasesMatthew H PorteusStanford University, USACV
SS04-3Autologous Stem Cell Transplantation in Pediatric Solid Tumor: Clinical Benefit and Late EffectJi Won LeeSungkyunkwan University School of Medicine, KoreaCV
Scientific Session 5: GVHD in 2023: From Prediction to Prevention
SS05-1New Insights into the Pathophysiology of GVHDTakanori TeshimaHokkaido University, JapanCV
SS05-2Predicting GVHD: From Biomarkers to Clinical Risk ScoreMargaret MacMillanUniversity of Minnesota, USACV
SS05-3Post-Transplant Cyclophosphamide as the New Standard for GVHD ProphylaxisByung-Su KimThe Catholic University of Korea, KoreaCV
Scientific Session 6: New Insights in the Immune Effector Cell Therapies for Multiple Myeloma
SS06-1Next Generation Immunotherapy in Multiple MyelomaThomas MartinUCSF Medical Center, USACV
SS06-2Clinical Utility of CAR T-Cells in Earlier-Lines in Multiple MyelomaSaad Z UsmaniMemorial Sloan Kettering Cancer Center, USACV
SS06-3Predictors of Response and Resistance of CAT-T or BsAb TherapyYi LinMayo Clinic, USACV
SS06-4Prognostic Values of MRD Status after CAR-T or BsAb TherapiesBruno PaivaThe University of Navarra, SpainCV
Scientific Session 7: Strategies for Successful Cord Blood Transplantation
SS07-1Recent Update of Cord Blood Transplantation in AdultDong-Yeop ShinSeoul National University College of Medicine, KoreaCV
SS07-2Experience of Cord Blood Transplantation in JapanSatoshi TakahashiThe University of Tokyo, JapanCV
SS07-3Experience of Cord Blood Transplantation in USAFilippo MilanoFred Hutchinson Cancer Center, USACV
SS07-4The Status of Cord Blood Banks (CBBs) for Unrelated Hematopoietic Stem Cell Transplantation (UR-HCT) & its Management of CBBs in KoreaJung Lim LeeDaegu Fatima Hospital, KoreaCV
Scientific Session 8: Bone Marrow Microenvironment in Hematologic Malignancy
SS08-1The Bone Marrow Microenvironment in Myeloid LeukemiaDaniela KrauseGoethe University Frankfurt, GermanyCV
SS08-2PDE4B is a Potential Therapeutic Target to Disrupt the Interplay between Lymphomas and the Bone Marrow MicroenvironmentSang-Woo KimPusan National University, KoreaCV
SS08-3The Bone Marrow Microenvironment in Multiple MyelomaYoon Seok ChoiAjou Universitry School of Medicine, KoreaCV
Scientific Session 9: Finding New Era of Haploidentical HSCT
SS09-1PTCY Alone vs. PTCY+ATG Combination in Haploidentical HSCTHee Young JuSungkyunkwan University School of Medicine, KoreaCV
SS09-2Understanding How T and NK Cells Mediate the GVL Effect without GVHD in Haploidentical HSCT: Insights into Biological MechanismsLoredana RuggeriUniversity of Perugia, ItalyCV
SS09-3Regimen Intensity and the Role of Total Body Irradiation in Haploidentical HSCTJongheon JungNational Cancer Center, KoreaCV
Scientific Session 10: Data to Clinic for Better Stem Cell Transplantation
SS10-1Electronic Health Record Use for Hematopoietic Cell Transplantation ResearchSung Won ChoiUniversity of Michigan, USACV
SS10-2Artificial Intelligence in Stem Cell TransplantationShahrukh K. HashmiSheikh Shakhbout Medical City, UAECV
SS10-3Recent Advances in Artificial Intelligence in HealthcareYoonjae ChoiKAIST, KoreaCV
Scientific Session 11: Pediatric Leukemia: Recent Advances in Treatments
SS11-1Real World CAR-T in Pediatric PatientsTheodore W. LaetschThe Children's Hospital of Philadelphia, USACV
SS11-2Pediatric Leukemia in the MRD Era (MRD Guided Treatment)Hiroto InabaSt. Jude Children's Research Hospital, USACV
SS11-3Hematopoietic Stem Cell Transplantation for Pediatric AMLDaisuke TomizawaNational Center for Child Health and Development, JapanCV
Scientific Session 12: Optimizing HSCT Outcomes in Patients with High-Risk AML
SS12-1The Role of MRD Monitoring and MRD-Directed Therapy in Patients with AMLJae-Sook AhnChonnam National University Medical School, KoreaCV
SS12-2Venetoclax Combination Therapy as a Bridging for HSCT in Elderly or Unfit AMLMaximilian StahlDana-Farber Cancer Institute, USACV
SS12-3HSCT for Elderly Patients With AML or MDS: Geriatric Assessment and Transplant DecisionGi June MinThe Catholic University of Korea, KoreaCV
Scientific Session 13: Recent Advances in Cellular Immunotherapy
SS13-1Tumor Microenvironment in CAR T-Cell TherapySaad S. KenderianMayo Clinic, USACV
SS13-2Engineered T Cells Produced From “Alternative Cellular Sources”Hiroshi KawamotoKyoto University, JapanCV
SS13-3TCR-T Cells for CancerPremal D. LullaBaylor College of Medicine, USACV
SS13-4Revolutionizing Solid Tumor Immunotherapy with CAR-NK CellsMihue JangKIST, KoreaCV
Joint Symposium 1 (ASTCT-KSBMT): Is HSCT still Relevant in Immunotherapy Era for Lymphoid Malignancies?
JS01-1Cell Therapies for Lymphoid MalignanciesHyunsoo ChoYonsei University College of Medicine, KoreaCV
JS01-2Pediatrics PerspectiveRayne RouceBaylor College of Medicine, USACV
JS01-3Stem Cell TransplantJulie VoseUniversity of Nebraska Medical Center, USACV
Joint Symposium 2 (TSBMT-KSBMT): Experiences and Future Perspectives on Transplantation and Cellular Therapy for Multiple Myeloma
JS02-1Cellular Therapies in Multiple Myeloma: Revolutionizing Treatment ApproachesAhmet Kursad GunesAnkara Etlik City Hospital, TürkiyeCV
JS02-2Bispecific Antibodies in Multiple MyelomaJa Min ByunSeoul National University College of Medicine, KoreaCV
Joint Symposium 3 (EBMT-KSBMT): Recent Issues in HSCT and Cellular Therapy for ALL
JS03-1The Role of Allogeneic Stem Cell Transplantation in Philadelphia positive ALL in the Era of Targeted TherapySebastian GiebelMaria Sklodowska-Curie National Research Institute of Oncology, PolandCV
JS03-2CAR T-Cells in Pediatric Patients with B-cell Acute Lymphoblastic Leukemia Vanderson RochaUniversity of São Paulo, BrazilCV
JS03-3Collaboration for the National Clinical Trials in Relapsed Pediatric and Adolescent Acute Lymphoblastic Leukemia in KoreaHyery KimUniversity of Ulsan College of Medicine, KoreaCV
JS03-4Treatment of Adult Acute Lymphoblastic Leukemia in KoreaHan-Seung ParkUniversity of Ulsan College of Medicine, KoreaCV
Joint Symposium 5 (ISCT-KSBMT): Industry-Academia Bridging in Cellular Therapy: Synergies and Challenges
JS05-1Cell & Gene Therapy Market & CDMO Business in Korea Sun Jae Kwon ENCell Co., Ltd., KoreaCV
JS05-2AAV Vectors as the Most Popular Viral Gene Delivery SystemKeerang ParkCdmoGen Co., Ltd., KoreaCV
Joint Symposium 6 (JSTCT-KSBMT): Recent Updates on the Management of MDS and JMML
JS06-1Prognostic Factors in Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Myelodysplastic Neoplasms: Retrospective Studies from a Nationwide Registry Data in JapanHidehiro ItonagaNagasaki University, JapanCV
JS06-2Hematopoietic Cell Transplantation for Pediatric Myelodysplastic Syndrome in Japan: JSTCT Pediatric MDS Working Group StudyShohei YamamotoTokai University, JapanCV
JS06-3Which Donor to Use for Patients with Myelodysplastic Syndrome?Joon Ho MoonKyungpook National University School of Medicine, KoreaCV
JS06-4Characteristics and Clinical Outcomes of Juvenile Myelomonocytic Leukemia in KoreaEun Sang YiKorea University College of Medicine, KoreaCV
East Asia Collaborative Session
Current Status of CAR-T Cell Therapy: Real-World Practice and Clinical Trials
JS04-1CAR T Therapy for Hematological Diseases in TaiwanBor-Sheng KoNational Taiwan University Cancer Center, TaiwanCV
JS04-2CAR T-Cell Therapy in ChinaHe HuangThe First Affiliated Hospital, Zhejiang University School of Medicine, ChinaCV
JS04-3Current Status and Future Directions in CAR T-Cell Therapy for Lymphoma in KoreaDok Hyun YoonUniversity of Ulsan College of Medicine, KoreaCV
JS04-4Current Status and Challenges of CAR-T Therapy for Hematopoietic Malignancies Koji KatoKyushu University Graduate School of Medical Sciences, JapanCV
Education Session 1: Pathogenesis, Diagnosis, Treatment of Endothelial Damage Syndrome
ES01-1Overview of the Endothelial Dysfunction after HSCTJunshik HongSeoul National University College of Medicine, KoreaCV
ES01-2Review of TMA Based on the Harmonized Consensus OpinionSung Han KangUniversity of Ulsan College of Medicine, KoreaCV
ES01-3Veno-Occlusive Disease / Sinusoidal Obstruction SyndromeKa-Won KangKorea University College of Medicine, KoreaCV
Education Session 2: Conditioning Regimen in Transplant Setting
ES02-1Conditioning Regimens: TBI and Non-TBI RegimensJae-Ho YoonThe Catholic University of Korea, KoreaCV
ES02-2Dose Intensity for Conditioning in Allogeneic Hematopoietic Cell Transplantation: Reduced Intensity Conditioning Versus. Myeloablative ConditioningYunsuk ChoiUniversity of Ulsan College of Medicine, KoreaCV
ES02-3Novel Conditioning Regimens for Hematopoietic Cell TransplantationSungnam LimInje University College of Medicine, KoreaCV
Education Session 3: Prevention and Management of Virus Disease in HSCT Patients
ES03-1How Do I Prevent and Manage COVID-19 Infection after HSCT?Pyoeng Gyun ChoeSeoul National University College of Medicine, KoreaCV
ES03-2How I Prevent and Manage CMV And Herpes Infection after HSCT?Yae-Jean KimSungkyunkwan University School of Medicine, KoreaCV
ES03-3How I Prevent and Manage HBV Reactivation after HSCT?Su Jong YuSeoul National University College of Medicine, KoreaCV
Education Session 4: Current and Future Direction in Chronic GVHD
ES04-1Clinical Diagnosis and Prophylaxis of Chronic GVHDEun-Ji ChoiUniversity of Ulsan College of Medicine, KoreaCV
ES04-2Novel Treatment and Sequence for Steroid-Refractory Chronic GVHDEunyoung LeeNational Cancer Center, KoreaCV
ES04-3Multidisciplinary Care to Improve Outcome of Chronic GVHDSeo-Yeon AhnChonnam National University Medical School, KoreaCV
Debate Session1: Mismatched Unrelated vs. Haploidentical
DS01-1Mismatched Unrelated Hematopoietic Stem Cell TransplantationSung-Hoon JungChonnam National University Medical School, KoreaCV
DS01-2HaploidenticalJae-Cheol JoUniversity of Ulsan College of Medicine, KoreaCV
Debate Session 2: Consolidative SCT or not after CAR T-Cell in ALL
DS02-1The Role Consolidative HSCT Following CAR T-cell Therapy in Children and Young Adults with B-ALLJae Won YooThe Catholic University of Korea, KoreaCV
DS02-2Optimizing CAR-T Therapy in PediatricsSeung min HahnYonsei University College of Medicine, KoreaCV
Nursing Session 1: Hematology Patients Care in the Digital Era (Panel discussion)
NS01-1Real-world data (RWD): One step closer to the truthSeunghoon HanThe Catholic University of Korea, KoreaCV
NS01-2From RWD To Real-World-Evidence (RWE) in Hematologic Disease Sung-Soo ParkThe Catholic University of Korea, KoreaCV
NS01-3Improving Diabetes Treatment Access and Outcomes Using Integrating Technology - Diabetes Mobile Apps -Kang Hee SimSamsung Medical Center, KoreaCV
NS01-4Introduction to Digital Therapeutics for Real-Time Symptom Monitoring and Providing Severity-Dependent Patient Advice Guiding Self Management or Medical Contact for Oncology PatientsJihyon YounAll Round Doctors, KoreaCV
Nursing Session 2: Future Strategy
NS02-1Precision Medicine in Hematologic DiseaseSheehyun KimSeoul National University College of Medicine, KoreaCV
NS02-2Clinical Experience of Covid-19 in Hematologic PatientsChang Kyung KangSeoul National University College of Medicine, KoreaCV
NS02-3Emergency Preparedness and Response in Nursing During Unpredictable PandemicJae Geum RyuChodang University, KoreaCV
Luncheon Symposium 1: Sanofi Aventis Korea
LS01How Do I Avoid Complication of Chronic GVHD?Bipin SavaniVanderbilt University Medical Center, USACV
Luncheon Symposium 2: BMS KOREA
LS02Oral Azacitidine Maintenance Therapy after Intensive Chemotherapy for Transplant-Ineligible AML PatientsMichael PfeilstöckerHanusch Hospital, AustriaCV
Luncheon Symposium 3: Handok Inc.
LS03Tafasitamab Efficacy and Safety in DLBCLGilles SallesMemorial Sloan Kettering Cancer Center, USACV
Luncheon Symposium 4: Gilead Science Korea Ltd.
LS04What is Missing in Hematology?Dong-Gun LeeThe Catholic University of Korea, KoreaCV
Luncheon Symposium 5: MSD KOREA
LS05CMV Prophylaxis in Letermovir EraJeong-Ok LeeSeoul National University College of Medicine, KoreaCV
Luncheon Symposium 6: Kyowa Kirin Korea
LS06Mogamulizumab for the Treatment of MF and SSYoun H KimStanford University School of Medicine, USACV
Luncheon Symposium 7: Astellas Phama Korea.Inc
LS07Emerging Approach to Improving Treatment Outcome of FLT3 Mutated Relapsed/Refractory AMLNaval DaverMD Anderson Cancer Center, USACV
Luncheon Symposium 8: Janssen Korea
LS08CD38 Antibodies in Multiple Myeloma: Molecular Mechanisms of ResistanceSophia AdamiaHarvard Medical School / BIDMC, USACV
Luncheon Symposium 9: Novartis Korea
LS09Reaching for the Real-world Benefits in GvHDCorey CutlerDana-Farber / Harvard Cancer Center, USACV